Gemin X Pharmaceuticals

About:

Gemin X Pharmaceuticals develops and commercializes targeted cancer therapeutics to improve the lives of patients.

Website: http://www.geminx.com

Top Investors: H.I.G. Capital, Fonds de solidarité FTQ, Ontario Teachers' Pension Plan, BDC Venture Capital, Business Development Bank of Canada

Description:

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.